名称何妨?特发性肺纤维化更名之争
本文为关于特发性肺纤维化(IPF)命名的观点文章,讨论IPF术语的临床与转化价值,并提出未来可能通过「拆分」为选择性应答亚组或「合并」为进展性纤维化表型来重新分类,强调在缺乏充分理由时更名弊大于利。
要点
- IPF仍属特发性,非家族性病例整体病因未明。
- 未来可能按进展性纤维化表型重新分类而非仅凭IPF名称。
- 无充分理由更名可能造成混淆,收益或不及代价。
核心结论
- IPF名称的变更需有重大概念变化作为依据,否则更名带来的困惑可能超过收益。
研究设计与样本
- 本文为观点文章(perspective),总结支持关注「进展性纤维化表型」的临床与发病机制依据。
主要发现
- IPF仍为真正的特发性纤维化疾病,仅有轻度遗传易感性及候选触发因素,非家族性病例整体病因未明。
- 自本千年以来术语共识推动了临床与转化研究的重大进展。
- 未来十年IPF可能通过「拆分」为对个体疾病修饰药物选择性应答的亚组或「合并」为进展性纤维化肺病而重新分类。
- 正在进行的非IPF进展性纤维化患者抗纤维化治疗试验可能具有高度影响力。
临床怎么用
- 关注「进展性纤维化表型」以覆盖非IPF进展性纤维化患者。
- 在缺乏充分理由时避免对IPF更名,以减少临床混淆。
局限性
- 本文为观点文章,未提供系统检索范围或汇总的原始研究数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) remains a truly idiopathic fibrotic disease, with a modest genetic predilection and candidate triggers but no overall explanation for the development of disease in non-familial cases. Agreement on terminology has contributed to major clinical and translational advances since the millennium. It is likely that the entity currently captured by the term "IPF" will be radically reclassified over the next decade, either through "splitting" (into IPF subgroups responding selectively to individual disease-modifying agents) or through "lumping" of IPF with other forms of progressive fibrotic lung disease (with shared pathogenetic mechanisms and IPF-like disease behaviour). In this perspective, we summarise the clinical and pathogenetic justification for a focus on "the progressive fibrotic phenotype" in future clinical and translational research. By this means, we can hope to address the needs of non-IPF patients with inexorably progressive fibrotic disease, currently disenfranchised by lack of access to agents that are efficacious in IPF. In this regard, ongoing trials of anti-fibrotic therapies in non-IPF patients with progressive fibrosis may be highly influential. Future revision of IPF nomenclature may be warranted if there are major conceptual changes but without compelling justification, the benefits of renaming IPF are likely to be outweighed by the resulting confusion.
引用
- Wells AU, Brown KK, Flaherty KR, et al. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018. PMID: 29773608. doi:10.1183/13993003.00692-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。